Heart shield: common drug may prevent Chemo-Induced cardiac harm
NCT ID NCT07370506
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether telmisartan, a blood pressure medication, can prevent heart damage caused by the chemotherapy drug doxorubicin in breast cancer patients. Researchers will enroll 36 newly diagnosed women and measure changes in heart function and injury markers. If effective, this approach could make chemotherapy safer without reducing its cancer-fighting power.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta University
Tanta, El Gharbia, 31111, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?